Suppr超能文献

cT3期低位直肠癌:预后因素分析

Stage cT3 low rectal cancer: analysis of prognostic factors.

作者信息

Li Fan, Chen Jin-Hai, Liu Yang, Guan Guo-Xian, Lu Chuan-Hui

机构信息

Department of Colorectal Surgery, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.

The Third Clinical Medical College, Fujian Medical University, Fuzhou, China.

出版信息

J Gastrointest Oncol. 2022 Apr;13(2):672-682. doi: 10.21037/jgo-22-269.

Abstract

BACKGROUND

Whether all cT3 low rectal cancer patients should receive neoadjuvant chemoradiotherapy (nCRT) remains controversial. The depth of invasion beyond the muscularis propria of the cT3 rectal cancer is of great significance to the selection of a treatment plan and the evaluation of prognosis.

METHODS

A retrospective analysis was conducted of 187 patients with stage cT3 low rectal cancer, who had been treated at the Department of Colorectal Surgery, The First Affiliated Hospital of Xiamen University from June 2010 to December 2012. The patients were divided into the nCRT group (88 cases) and no-nCRT group (99 cases). Possible significant prognostic factors [i.e., primary tumor volume (PTV), cell differentiation, circumferential resection margin (CRM), nCRT, age, sex, carcinoembryonic antigen (CEA), lymph node status, surgical procedure, etc.] were collected for estimation of disease-free survival (DFS), distant metastases rate (DM), local recurrence rate (LR). Independent predictive factors or survival were determined using Cox proportional hazards model.

RESULTS

The mean PTV was 16.2±11.1 (2.07-72.68) cm. In the univariate and multivariate analyses: nCRT hazards ratio (HR) =4.258, 95% confidence interval (CI): 1.912-9.483 (P<0.001); PTV HR =0.381, 95% CI: 0.181-0.804 (P=0.011); CRM HR =0.227, 95% CI: 0.097-0.532 (P=0.001). For the PTV ≤15 cm group, there were no significant differences between the nCRT and no-nCRT group in 3-year follow-up (P>0.05). For the PTV >15 cm group, there were significant differences between the nCRT and no-nCRT group in 3-year DFS (84.2% 51.1%; P=0.001), DM (13.1% 31.2%; P=0.017) and LR (2.9% 26.6%; P=0.009). For the CRM negative group, there were significant differences between the nCRT and no-nCRT group in 3-year DFS (94.0% 79.0%; P=0.008), LR (1.5% 10.7%; P=0.028) and DM (4.5% 13.5%; P=0.039).

CONCLUSIONS

For stage cT3 low rectal cancer patients, nCRT, PTV, and CRM were independent prognostic factors. NCRT may improve the survival of PTV >15 cm patients, but may not have a significant effect on patient with PTV ≤15 cm and CRM negative. Direct surgery is recommended for this group of patients.

摘要

背景

所有cT3期低位直肠癌患者是否均应接受新辅助放化疗(nCRT)仍存在争议。cT3期直肠癌侵犯至固有肌层以外的深度对于治疗方案的选择及预后评估具有重要意义。

方法

对2010年6月至2012年12月在厦门大学附属第一医院结直肠外科接受治疗的187例cT3期低位直肠癌患者进行回顾性分析。将患者分为nCRT组(88例)和非nCRT组(99例)。收集可能的重要预后因素[即原发肿瘤体积(PTV)、细胞分化程度、环周切缘(CRM)、nCRT、年龄、性别、癌胚抗原(CEA)、淋巴结状态、手术方式等],以评估无病生存期(DFS)、远处转移率(DM)、局部复发率(LR)。采用Cox比例风险模型确定生存的独立预测因素。

结果

PTV均值为16.2±11.1(2.07 - 72.68)cm。单因素和多因素分析显示:nCRT风险比(HR)=4.258,95%置信区间(CI):1.912 - 9.483(P<0.001);PTV HR =0.381,95% CI:0.181 - 0.804(P=0.011);CRM HR =0.227,95% CI:0.097 - 0.532(P=0.001)。对于PTV≤15 cm组,nCRT组和非nCRT组在3年随访中无显著差异(P>0.05)。对于PTV>15 cm组,nCRT组和非nCRT组在3年DFS(84.2%对51.1%;P=0.001)、DM(13.1%对31.2%;P=0.017)和LR(2.9%对26.6%;P=0.009)方面存在显著差异。对于CRM阴性组,nCRT组和非nCRT组在3年DFS(94.0%对79.0%;P=0.008)、LR(1.5%对10.7%;P=0.028)和DM(4.5%对13.5%;P=0.039)方面存在显著差异。

结论

对于cT3期低位直肠癌患者,nCRT、PTV和CRM是独立的预后因素。NCRT可能改善PTV>15 cm患者的生存,但对PTV≤15 cm且CRM阴性的患者可能无显著影响。建议该组患者直接手术。

相似文献

1
Stage cT3 low rectal cancer: analysis of prognostic factors.
J Gastrointest Oncol. 2022 Apr;13(2):672-682. doi: 10.21037/jgo-22-269.
2
[Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Mar 25;23(3):281-288. doi: 10.3760/cma.j.cn.441530-20200228-00096.
7
Low- Versus High-Risk Rectal Cancer Based on MRI Features: Outcomes in Patients Treated Without Neoadjuvant Chemoradiotherapy.
AJR Am J Roentgenol. 2018 Aug;211(2):327-334. doi: 10.2214/AJR.17.18980. Epub 2018 Jun 21.
8
Prognostic Value of the Circumferential Resection Margin in Esophageal Cancer Patients After Neoadjuvant Chemoradiotherapy.
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1301-9. doi: 10.1245/s10434-015-4827-2. Epub 2015 Aug 28.
10
[Clinicopathological and prognostic features of young onset patients with middle-low rectal cancer received neoadjuvant chemoradiotherapy].
Zhonghua Zhong Liu Za Zhi. 2021 May 23;43(5):574-580. doi: 10.3760/cma.j.cn112152-20201220-01083.

引用本文的文献

1
Relationship between apparent diffusion coefficient values and clinicopathologic features in rectal cancer: a cross-sectional study.
J Gastrointest Oncol. 2025 Apr 30;16(2):528-541. doi: 10.21037/jgo-24-831. Epub 2025 Apr 27.

本文引用的文献

2
Better prognostic determination of cT3 rectal cancer through measurement of distance to mesorectal fascia: A multicenter study.
Chin J Cancer Res. 2021 Oct 31;33(5):606-615. doi: 10.21147/j.issn.1000-9604.2021.05.07.
3
NCCN Guidelines Insights: Rectal Cancer, Version 6.2020.
J Natl Compr Canc Netw. 2020 Jul;18(7):806-815. doi: 10.6004/jnccn.2020.0032.
5
Limitation of radiological T3 subclassification of rectal cancer due to paucity of mesorectal fat in Chinese patients.
Hong Kong Med J. 2014 Oct;20(5):366-70. doi: 10.12809/hkmj144232. Epub 2014 Aug 1.
6
Utility of reassessment after neoadjuvant therapy and difficulties in interpretation.
Diagn Interv Imaging. 2014 May;95(5):495-503. doi: 10.1016/j.diii.2014.03.010. Epub 2014 Apr 22.
8
Depth of mesorectal extension has prognostic significance in patients with T3 rectal cancer.
Dis Colon Rectum. 2012 Dec;55(12):1220-8. doi: 10.1097/DCR.0b013e31826fea6a.
10
Does t3 subdivision correlate with nodal or distant metastasis in colorectal cancer?
J Korean Soc Coloproctol. 2012 Jun;28(3):160-4. doi: 10.3393/jksc.2012.28.3.160. Epub 2012 Jun 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验